Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.58 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.48 |
| ▸ | FDPS | P14324 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | KDM5A | P29375 | 4/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 4/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8980674 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL15236225 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL8980621 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL8980557 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL8980618 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL4687503 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL20345235 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL8980767 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| Hydrochloric Acid SCHEMBL22771590 | 0.97 | DNM1 (0.60) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL8980627 | 0.97 | DNM1 (0.63) | DNM1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025848-A1 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-25 | — | — | US | disclosed |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | RECODE THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023089052-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023049364-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS SODIUM CHANNEL ACTIVATORS | XENON PHARMACEUTICALS INC. (CA) | 2023-03-30 | — | — | WO | disclosed |
| US-20220152251-A1 | Non-Aqueous PS/ICP Systems And Application To Surfaces | Mi2 Holdings LLC (US) | 2022-05-19 | — | — | US | disclosed |
| US-11166947-B2 | Effective dosing of a child for the treatment of ADHD with methylphenidate | NEOS THERAPEUTICS, LP (US) | 2021-11-09 | — | — | US | disclosed |
| US-11110082-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-10913948-B2 | RNA interference in dermal and fibrotic indications | PHIO PHARMACEUTICALS CORP. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-2052011-B1 | TARGETED POLYLYSINE DENDRIMER THERAPEUTIC AGENT | STARPHARMA PTY LTD (AU) | 2020-11-04 | — | — | EP | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | NEUROGEN CORPORATION (US) | 2007-02-22 | — | — | US | disclosed |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | NEUROGEN CORPORATION | 2007-02-01 | — | — | US | disclosed |
| US-5652247-A | VASOPRESSIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 1997-07-29 | — | — | US | disclosed |
| US-5436254-A | Vaopressin antagonists | OTSUKA PHARMACEUTICAL COMPANY, LTD. (JP) | 1995-07-25 | — | — | US | disclosed |
| EP-0602209-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0382185-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1994-06-15 | — | — | EP | disclosed |
| WO-1994001113-A1 | OXYTOCIN ANTAGONIST | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1994-01-20 | — | — | WO | disclosed |
| US-5225402-A | Vasopressin antagonist, vasodilation, hypotensive, diuretics and anticoagulants | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-07-06 | — | — | US | disclosed |
| EP-0382185-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043049-A1 | Substituted heterocyclic diarylamine analogues | GPR35, NPY1R, BDKRB1 | DNM1 1913/4885S1PR2 1068/4885S1PR1 854/4885 |
| US-20240025848-A1 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | LIPA, LIPC, TLR9 | DNM1 84/4885S1PR2 623/4885S1PR1 876/4885 |
| US-11110082-B2 | Tyrosine kinase inhibitors | TYRO3, AXL, RET | DNM1 3806/4885S1PR2 2292/4885S1PR1 1797/4885 |
| US-20230293429-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | CHMP4B, LIPA, NPC1L1 | DNM1 307/4885S1PR2 677/4885S1PR1 595/4885 |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | DGKB, DGKG, DGKA | DNM1 625/4885S1PR2 1483/4885S1PR1 1622/4885 |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | DNM1 2018/4885S1PR2 259/4885S1PR1 253/4885 |
| US-20070027155-A1 | Biaryl piperazinyl-pyridine analogues | GPR174, GPR68, PPARG | DNM1 1159/4885S1PR2 400/4885S1PR1 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.